The (ir)relevance of plasma protein binding of anticancer drugs

Netherlands Journal of Medicine

Volumn 59, Issue 4, 2001, Pages 196-207

  Sparreboom, Alex ^a   Nooter, Kees ^a   Loos, Walter J ^a   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Anticancer drugs; Binding; Clinical pharmacology; Pharmacokinetics; Plasma proteins

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 HYDROXYSTAUROSPORINE; AMSACRINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BREQUINAR; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PROTEIN; TAMOXIFEN; TENIPOSIDE; THIOTEPA; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG;

ANALYTIC METHOD; CLINICAL TRIAL; COVALENT BOND; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; PLASMA PROTEIN BINDING; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); BLOOD PROTEINS; CARRIER PROTEINS; CHEMISTRY, PHARMACEUTICAL; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG MONITORING; FORECASTING; HUMANS; METABOLIC CLEARANCE RATE; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0034801877     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(01)00157-7     Document Type: Review

References (96)

1. Pharmacokinetically guided administration of chemotherapeutic agents
2. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function
3. Pharmacokinetics of anticancer agents in patients with impaired liver function
4. Protein binding and drug clearance
5. Plasma and tissue binding considerations in drug disposition
6. Covalent and noncovalent binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery
7. Plasma protein binding of chemotherapeutic agents
8. Pharmacokinetics of alkylating agents
9. Protein binding of diphenylhydantoin and demethylimipramide in plasma from patients with poor renal function
10. Structure and ligand binding properties of human serum albumin
11. Age-related changes in protein binding of drugs: Implications for therapy
12. Increased plasma binding of quinidine after surgery: A preliminary report
13. Serum glycoproteins and malignant neoplastic diseases
14. Serum glycoproteins in cancer
15. Albumin metabolism in neoplastic diseases
16. Influence of protein binding and use of unbound (free) drug concentrations
17. An abnormal orosomucoid in the plasma of patients with neoplastic disease
18. Clearance concepts in pharmacokinetics
19. Concepts basic to pharmacokinetics
20. The binding of amsacrine to human plasma proteins
21. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function
22. Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients
23. Binding of busulfan to plasma proteins and blood cells
24. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
25. Studies on the pharmacokinetics of chlorambucil and prednimustine in man
26. Cisplatin binding sites on human albumin
27. Metabolism and pharmacokinetics of oxazaphosphorines
28. Cytosine arabinoside binding to human plasma proteins
29. Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside
30. 1-acid glycoprotein
31. Protein binding of anthraquinone glycosides, with special reference to adriamycin
32. Equilibrium binding of anthracycline cytostatics to serum albumin and small unilamellar phospholipid vesicles as measured by gel filtration
33. Altered protein binding of etoposide in patients with cancer
34. The binding of 5-fluorouracil to serum protein fractions, erythrocytes and ghosts under in vitro conditions
35. Preclinical pharmacokinetics and stability of isophosphoramide mustard
36. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood
37. Renal clearance and protein binding of melphalan in patients with cancer
38. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma
39. Binding of drugs to human serum albumin XVII: Irreversible binding of mercaptopurine to human serum proteins
40. In vitro and in vivo protein binding of methotrexate assessed by microdialysis
41. Methotrexate binding to human plasma proteins
42. Clinical pharmacokinetics of oxaliplatin: A critical review
43. Binding of taxol to human plasma, albumin, and alpha 1-acid glycoprotein
44. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
45. In vitro protein binding of CPT-11 metabolites SN-38, SN-38 glucuronide (SN-38G), and APC and possible displacement by commonly used co-medications
46. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan
47. Binding of toremifene to human serum proteins
48. Human albumin binding of tamoxifen in the presence of a perfluorochemical erythrocyte substitute
49. Variability in teniposide plasma protein binding is correlated with serum albumin concentrations
50. The binding of thio-TEPA in human serum and to isolated serum protein fractions
51. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability
52. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
53. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks
54. 1-acid glycoprotein
55. 1-acid glycoprotein in humans
56. Binding of vinblastine to recrystallized human alpha 1-acid glycoprotein
57. The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease
58. Vinorelbine high-affinity binding to human platelets and lymphocytes: Distribution in human blood
59. Plasma protein binding displacement interactions - Why are they still regarded as clinically important?
60. What is the true clinical significance of plasma protein binding displacement interactions?
61. Disposition of total and unbound etoposide following high-dose therapy
62. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction
63. Factors affecting in vitro protein binding of etoposide in humans
64. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients
65. Relation of systemic exposure to unbound etoposide and hematologic toxicity
66. Etoposide dosage and pharmacodynamics
67. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphoblastic leukemia
68. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II)
69. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion
70. Protein binding, sister chromatid exchange and expression of oncogene proteins in patients treated with cisplatinum (cisDDP)-based chemotherapy
71. Irreversible binding of cisplatin in rat serum
72. Platinum compounds: Pharmacokinetics and pharmacodynamics
73. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin
74. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)
75. Phase I study of liposomal vincristine
76. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: Implications for pharmacokinetic studies
77. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
78. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma
79. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques
80. A rapid method for the separation and analysis of leaked and liposomal entrapped phosphoramide mustard in plasma
81. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods
82. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles
83. Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients
84. Measurement of fraction unbound paclitaxel in human plasma
85. Mechanism based pharmacokinetic model for paclitaxel
86. Modulation of camptothecin analogues in the treatment of cancer: A review
87. Differential interactions of camptothecin lactone and carboxylate forms with human blood components
88. Reduced albumin binding promotes the stability and activity of topotecan in human blood
89. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study
90. Role of erythrocytes and serum proteins in the kinetic profiles of total 9-amino-20(S)-camptothecin in humans
91. Clinical pharmacokinetics of oral 9-aminocamptothecin in plasma and saliva
92. Determination of camptothecin analogues in biological matrices by high-performance liquid chromatography
93. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding
94. Drug-protein binding studies. New trends in analytical and experimental methodology